Caribou Biosciences to Evaluate Strategic Alternatives

Company to evaluate strategic alternatives to maximize stockholder value ---- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs ---- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 --BERKELEY, Calif., Oct. 06, 2026 (G…